Abstract: Methods are provided for treating or preventing human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) in a virologically suppressed patient in need thereof comprising switching the patient from an antiretroviral treatment regimen comprising at least three antiretroviral agents to a treatment regimen comprising only two antiretroviral agents. In one aspect the two treatment regimen consists of dolutegravir, rilpivirine and at least one pharmaceutically acceptable excipient, diluent or carrier. In another aspect of the invention, there is provided a multilayer tablet comprising dolutegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
November 7, 2023
Publication date:
March 21, 2024
Applicants:
ViiV Healthcare Company, Janssen Sciences Ireland Unlimited Company
Inventors:
Kenneth Churchill CAMPBELL, Urbain Alfons C. DELAET, James M. GOODRICH, Juliette Segolène GUAQUIÈRE, Thomas LAUGHERY, Dominique J. LIMET, John C. POTTAGE, Ludovic Sylvain Marc RENOU, Trevor R. SCOTT, Christian SEILER, Mary WOODWARD
Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
Type:
Application
Filed:
August 31, 2022
Publication date:
February 15, 2024
Applicants:
GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
Inventors:
Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
Abstract: The present invention relates to formulations comprising dolutegravir or a pharmaceutically acceptable salt thereof, processes for making such formulations, and the use of such formulations in the treatment of HIV infection, in particular in the treatment of HIV infection in pediatric patients.
Type:
Application
Filed:
June 23, 2021
Publication date:
September 14, 2023
Applicant:
ViiV Healthcare Company
Inventors:
Ian Paul CONN, Mark Robert DAVIES, Joanne HEAFIELD, Michael HOLTON, Neil MORTIMER
Abstract: The present invention relates to formulations comprising dolutegravir or a pharmaceutically acceptable salt thereof, abacavir or a pharmaceutically acceptable salt thereof and lamivudine, processes for making such formulations, and the use of such formulations in the treatment of HIV infection, in particular in the treatment of HIV infection in pediatric patients.
Type:
Application
Filed:
June 23, 2021
Publication date:
July 27, 2023
Applicant:
ViiV Healthcare Company
Inventors:
Ian Paul CONN, Mark Robert DAVIES, Jose Maria FUEYO, Joanne HEAFIELD, Trevor Martin SHREEVES
Abstract: The invention relates to compounds of Formula (I), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
Abstract: A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.
Type:
Grant
Filed:
July 18, 2018
Date of Patent:
January 31, 2023
Assignees:
ViiV Healthcare Company, Janssen Sciences Ireland Unlimited Company
Inventors:
Herta Crauwels, David Margolis, William R. Spreen, Andrew Spaltenstein, Peter Williams
Abstract: The invention relates to a compound having the structure: or a pharmaceutically acceptable salt thereof, along with pharmaceutical compositions and therapeutic methods thereof.
Type:
Application
Filed:
June 1, 2021
Publication date:
December 29, 2022
Applicants:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, VIIV HEALTHCARE COMPANY
Inventors:
Martha Alicia DE LA ROSA, John F. MILLER, B. Narasimhulu NAIDU, Vicente SAMANO, David TEMELKOFF, Emile Johann VELTHUISEN
Abstract: The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
Type:
Grant
Filed:
October 5, 2020
Date of Patent:
November 8, 2022
Assignees:
GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
Inventors:
Richard M. Dunham, David Margolis, Vincent Wing-Fai Tai, Jun Tang
Abstract: The invention relates to compounds of Formulae (I)-(II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
Type:
Application
Filed:
August 28, 2020
Publication date:
September 22, 2022
Applicants:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, VIIV HEALTHCARE COMPANY
Inventors:
Martha Alicia DE LA ROSA, John MILLER, Lita S. SUWANDI, David TEMELKOFF, Emile Johann VELTHUISEN
Abstract: The invention relates to compounds of Formulae (I) and (II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
Type:
Application
Filed:
July 30, 2020
Publication date:
August 18, 2022
Applicants:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, VIIV HEALTHCARE COMPANY
Inventors:
John MILLER, Vicente SAMANO, David TEMELKOFF, Emile Johann VELTHUISEN
Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
Type:
Application
Filed:
January 27, 2022
Publication date:
July 7, 2022
Applicants:
Shionogi & Co., Ltd., ViiV Healthcare Company
Inventors:
Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
Type:
Application
Filed:
August 6, 2021
Publication date:
April 21, 2022
Applicants:
GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
Inventors:
Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
Abstract: The invention relates to compounds of the Formula: salts thereof, pharmaceutical compositions thereof, combinations thereof, as well as therapeutic methods of treatment and prevention.
Type:
Application
Filed:
August 8, 2019
Publication date:
April 21, 2022
Applicants:
GlaxoSmithKline Intellectual Property (No. 2) Limited, VIIV Healthcare Company
Inventors:
John Franklin MILLER, David TEMELKOFF, Emile Johann VELTHUISEN, Martha Alicia DE LA ROSA, Lita SUWANDI, B. Narasimhulu NAIDU
Abstract: Invented are methods for treating HIV in a human in need thereof which comprises the administration of a therapeutically effective amount of a combination of dolutegravir or a pharmaceutically acceptable salt thereof and lamivudine or a pharmaceutically acceptable salt thereof, to such human.
Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
Type:
Grant
Filed:
July 9, 2020
Date of Patent:
March 8, 2022
Assignees:
SHIONOGI & CO., LTD., VIIV HEALTHCARE COMPANY
Inventors:
Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
Abstract: The present Invention relates to pharmaceutical compositions of (3S,11aR)—N-[(2,4-difluorophenyhmethyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
Abstract: The invention relates to compounds of Formulae (I), (Ia), (II) and (IIa), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
Type:
Application
Filed:
August 28, 2019
Publication date:
October 21, 2021
Applicants:
GlaxosmithKline Intellectual Property (No. 2) Limited, ViiV Healthcare Company
Inventors:
John MILLER, David TEMELKOFF, Emile Johann VELTHUISEN, Martha Alicia DE LA ROSA, Lisa SUWANDI
Abstract: The present invention is directed to N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide of the formula: or a pharmaceutically acceptable salt or stereoisomer thereof, and pharmaceutical compositions comprising the same. The present invention has HIV integrase inhibitory activity.
Type:
Grant
Filed:
May 1, 2019
Date of Patent:
February 23, 2021
Assignees:
SHINOGI & CO., LTD., VIIV HEALTHCARE COMPANY
Inventors:
Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
Abstract: The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
Type:
Application
Filed:
October 5, 2020
Publication date:
January 14, 2021
Applicants:
GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
Inventors:
Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG